The Virtual CVOT Summit 2022 will start on November 10 at 16:00 CET.The livestream will start today at 16:00 CET.Welcome and Introduction16:00 – 16:10 CETSchnell O (Munich, Germany)Update on CVD, HF, and CKD Treatment: The ADA-EASD Consensus Report 202216:10 – 16.25 Mathieu C (Leuven, Belgium)New pharmacotherapies for Type 2 Diabetes: a systematic review and network meta-analysis of randomised controlled trials16:25 – 16:40 Mustafa R (Kansas City, US)Diabetes and CVD: achieving guideline-recommended management at 12 months 16:40 – 16:55Green J (Durham, US)) Discussion16:55 – 17:10 Early Clinical Studies: Paving the road for outcomes trials in diabetes17:10 – 17:30Hompesch M (San Diego, US)Discussion17:30 – 17:40Subtypes of Type 2 Diabetes – Shaping cardiovascular risk17:40 – 18:00Birkenfeld A (Tuebingen, Germany)Discussion18:00 – 18:10 CGM for changing Type 2 Diabetes medication18:10 – 18:30 Bergenstal R (Minneapolis, US) Discussion18:30 – 18:40 Break18:40 – 19:00 CETWhy should we mind the intention-action gap in guideline implementation?19:00 – 19:10Kanumilli N (Manchester, UK) Deciphering guidelines – One voice on cardiorenal protection19:10 – 19:25Cheng A (Mississauga, Canada)Screening for CKD in PCP clinic19:25 – 19:40Rossing P (Copenhagen, Denmark) Never walk alone – Become a Guardian19:40 – 19:50Kanumilli N (Manchester, UK) Q&A, Summary and Closing19:50 – 20:00Cheng A (Mississauga, Canada) The Virtual CVOT Summit 2022 continues tomorrow, Friday November 11, at 08:30 CET. We look forward to your participation!The Virtual CVOT Summit 2022 continues tomorrow, Friday November 11, at 08:30 CET. We look forward to your participation!The livestream will start today at at 08:30 CET.Further merging new glycemic markers with outcomes in diabetes08:30 – 08:45Battelino T (Ljubljana, Slovenia)Combination therapy: When is the right time for insulin?08:45 – 09:00Giorgino F (Bari, Italy)Inhaled Insulin: Initiation and titration to improve time in range09:00 – 09:25 Pettus J (San Diego, US), Edelman S (San Diego, US)Discussion09:25 – 09:45 CKD: The importance of Real World Evidence (RWE) in clinical decision making 09:45 – 10:00 Pecoits-Filho R (Curitiba, Brasil)Real world evidence in CVD: strengths and weaknesses10:00 – 10:15Kanumilli N (Manchester, UK) OP 1: Risk of stroke in patients with Type 2 Diabetes receiving semaglutide or a dipeptidyl peptidase-4 inhibitor: A real-world US claims database analysis 10:15 – 10:25Evans M (Cardiff, UK)Discussion10:25 – 10:30Break10:30 – 11:00 CETTreatment of CKD: SGLT-2-inhibitors and future developments11:00 – 11:15Heerspink H (Groningen, Netherlands) GLP-1 RAs moving towards CKD: An update11:15 – 11:30Nauck M (Bochum, Germany)Management of CKD in diabetes - Targeting unmet needs11:30 – 11:45Groop PH (Helsinki, Finland)New treatment options for CKD in diabetes: Learnings from recent studies11:45 – 12:00Hadjadj S (Poitiers, France)Panel Discussion12:00 – 12:30Break12:30 – 13:00 CETMonitoring and screening of heart failure in diabetes: The increasing role of biomarkers13:00 – 13:20Ceriello A (Milan, Italy)Managing HFpEF with SGLT-2-inhibitors13:20 – 13:40Solomon S (Boston, US)OP 2: Effectiveness and safety of empagliflozin in routine care: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study13:40 – 13:50 Htoo PH (Boston, US)OP 3: Plasma mannose as a novel marker of myocardial infarction across different glycaemic states13:50 - 14:00Fortin E (Stockholm, Sweden)Panel Discussion14:00 – 14:30 CET Break14:30 – 15:00 CETPresent and future of weight management in obesity and diabetes15:00 – 15:20Wilding JPH (Liverpool, UK)Dual GIP/GLP Agonists: Guidelines and practical considerations in diabetes15:20 – 15:40 Davies M (Leicester, UK)Targeting obesity: High-dose GLP1-RAs and dual GIP/GLP Agonists15:40 – 16:00 Vilsbøll T (Copenhagen, Denmark)OP 4: Systolic blood pressure reduction with tirzepatide across SURPASS program: A mediation analysis using weight loss as a factor 16:00 – 16:10Ranta K (Indianapolis, US)Discussion16:10 – 16:30Industry´s perspective - panel discussion 16:30 – 17:30 CETOP 5: Effects of empagliflozin on markers of calcium and phosphate homeostasis in patients with Type 2 DiabetesRau M (Aachen, Germany)OP 6: Influence of continuous glucose monitoring on the glycemic control and quality of life in patients with Type 2 Diabetes mellitus and coronary heart diseaseSaienko Y (Kyiv, Ukraine)OP 7: Estimated glomerular filtration rate, mortality and MACE in men with hypogonadism and Type 2 Diabetes under long-term testosterone therapySaad F (Berlin, Germany)OP 8: Investigating the role of small nucleolar RNAs (snoRNAs) as an early genetic marker of future adverse cardiovascular eventsKumar U (Cambridge, UK)OP 9: Sodium-glucose CO-transporter inhibition in patients with newly detected Glucose Abnormalities and a recent Myocardial Infarction (SOCOGAMI)Ferrannini G (Stockholm, Sweden)Abstract Awards and Closing18:30 – 18:45 CET Schnell O (Munich, Germany) Thank you for your attendance and contribution to the Virtual CVOT Summit 2022.
See you next year for the 9th CVOT Summit on November 23 - 24, 2023.Thank you for your attendance and contribution to the Virtual CVOT Summit 2022.
See you next year for the 9th CVOT Summit on November 23 - 24, 2023.We will be right back.We are currently having some technical issues. We will be right back.The page is automatically updated.The next program item is loaded.
Log in with email address and password.
Free Registration and Password Creation
To log in you need to create a password: